[Clinical and experimental validation of the use of the tranquilizer mebikar as a corrective of the neuroleptic syndrome].

The results of the experimental and clinical studies showed that administration of mebikar in combination with neuroleptics reduced the degree of side effects of the neuroleptics without decreasing their antipsychotic effect.

[Pharmacological effects of combinations of psychotropic preparations used in combined pharmacotherapy].

It was shown in experiments on mice that inhibition of the exploratory activity by ftoracizin, phenazepam, scopolamine hydrobromide and their combinations predominates in comparison with muscle relaxation. Phenazepam administered at the low dose (0.025 mg/kg) by its depressive effect on the central nervous system was an antagonist of ftoracizin and a synergist of scopolamine.

[Evaluation of the nootropic effect of mebikar in clinical practice].

Mebicar therapy resulted in a reduction of the degree of deficient disorders of thinking in 27 of 50 patients with paranoid schizophrenia and normalization of indices of mental working capacity, attention and memory, shortening of the time of visual-motor disjunctive reaction in 50 patients with borderline states. Mebicar was shown to possess a nootropic effect which differs qualitatively from that of piracetam.

[Mechanisms of the antishock action of mebikar].

The tranquilizer mebicar produces an antishock action, normalizes different links of mediator, acid-base and oxygen homeostasis. Mebicar decreases arterial pressure and the tone of peripheral vessels insignificantly and for a short period.